Jarushka Naidoo: TL01 Phase III Datopotamab-Deruxtecan vs Docetaxel in second-line NSCLC

Jarushka Naidoo shared a post on X, about recent paper published in Journal of Clinical Oncology:

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Authors: Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons-Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, Maurice Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Min Hee Hong, Enriqueta Felip, Richard Hall, Oscar Juan-Vidal, Daniel Brungs, Shun Lu, Marina Garassino, Michael Chargualaf, Yong Zhang, Paul Howarth, Deise Uema, Aaron Lisberg, Jacob Sands.

”TL01 Phase III Datopotamab-Deruxtecan versus Docetaxel in second-line non-small cell lung cancer, Final Overall Survival from Journal of Clinical Oncology:

• Median progression-free survival 4.4 versus 3.7 months (hazard ratio 0.75, P=0.004).
• Median overall survival 12.9 versus 11.8 months (hazard ratio 0.94, P=0.530).
• Non-squamous median progression-free survival 5.5 versus 3.6 months; median overall survival 14.6 versus 12.3 months (hazard ratio 0.84, confidence interval crosses 1).

Concurrent presentation.”

Source: Jarushka Naidoo/X

Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.